Patent · US Active

Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

US11951190B2 · kind B2 · utility

2Cited by

226References

62Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Matthias Eder · Freiburg (Elbe), DE
Klaus Kopka · Dossenheim, DE
Martin SCHÄFER · Neckarsteinach, DE
Ulrike BAUDER-WÜST · Schriesheim, DE
Michael Eisenhut · Heidelberg, DE
Walter Mier · Bensheim, DE
Martina Benesova · Neckarsteinach, DE

Key dates

Filing date	Jan 7, 2021
Grant date	Apr 9, 2024
Priority date	—
Expiry date	Feb 2, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D295/145
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.